Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

120.31 +0.71 (+0.59%)

Streaming Delayed Price Updated: 2:15 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere ↗

June 20, 2025

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

Via Benzinga

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.

Via Benzinga

2 Reasons to Watch MRK and 1 to Stay Cautious

June 19, 2025

Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $79.30. This might have investors contemplating their next move.

Via StockStory

Topics Supply Chain

Price Over Earnings Overview: Merck & Co ↗

June 09, 2025

Via Benzinga

Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake ↗

June 18, 2025

Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound.

Via Benzinga

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 18, 2025

Via Benzinga

MERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentals ↗

June 18, 2025

MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors.

Via Chartmill

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

June 18, 2025

From Merck & Co., Inc.

Via Business Wire

2 Dividend Stocks to Buy and Never Sell ↗

June 18, 2025

Via The Motley Fool

Topics Lawsuit

3 Mega-Cap Stocks with Competitive Advantages

June 18, 2025

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their...

Via StockStory

Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills ↗

June 17, 2025

The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such...

Via Stocktwits

Topics Government

These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 ↗

June 14, 2025

The Dow Jones index could have fared better in May if not for these two stocks.

Via The Motley Fool

Topics Government Intellectual Property Lawsuit

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery ↗

June 13, 2025

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Via Benzinga

Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish ↗

June 13, 2025

In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said.

Via Stocktwits

Topics Death

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

June 13, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

June 12, 2025

From Merck & Co., Inc.

Via Business Wire

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit ↗

June 12, 2025

Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine.

Via Benzinga

Topics Lawsuit

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 12, 2025

Via Benzinga

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

June 12, 2025

From Merck & Co., Inc.

Via Business Wire

2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility ↗

June 12, 2025

Via The Motley Fool

Topics Artificial Intelligence Government

Unpacking the Latest Options Trading Trends in Merck & Co ↗

June 11, 2025

Via Benzinga

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

June 11, 2025

Via The Motley Fool

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

June 10, 2025

Via Benzinga

MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals ↗

June 10, 2025

MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors.

Via Chartmill

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season

June 09, 2025

From Merck & Co., Inc.

Via Business Wire

Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials ↗

June 09, 2025

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.

Via Benzinga

Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish ↗

June 09, 2025

Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide.

Via Stocktwits

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 09, 2025

Via Benzinga

Top S&P500 movers in Monday's pre-market session ↗

June 09, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.

Via Chartmill

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

June 09, 2025

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.